A new biotech called Dispatch Bio launched today with the goal of developing a new, universal approach to try to treat any cancer using immunotherapy.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced Wednesday that it expects its partner Sarepta Therapeutics (NASDAQ:SRPT), which recently withdrew its gene therapy Elevidys from the U.S. market, will ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, Itovebi (inavolisib), to be used alongside palbociclib and fulvestrant for breast ...